Navigation Links
World Renowned Champalimaud Foundation Extends its Mission with Groundbreaking for Cutting-Edge Research Center
Date:10/8/2008

e design of the facility. The ceremony was highlighted by a small robot placing the first stone in the building's foundation. This signified a new and advanced era of scientific exploration and discovery for Portugal. The Center will be built in a historic location, where the Tagus River joins the Atlantic Ocean -- the point from which 15th and 16th -century Portuguese explorers embarked on maritime journeys and discoveries. This location is also symbolic of the new discoveries in the world of science and disease treatment, which are expected to be made at this Center.

Bombay-based firm Charles Correa Associates is the Design Architect, in collaboration with RMJM Hillier as Laboratory and Clinical Design Architects and Consiste of Portugal as the Architect of record. The facility will have Diagnostic, Treatment, and Wellness Centers and an open-air amphitheatre facing the river for public performances. Also, the project will include high-performance buildings that employ optimal energy and resource management. The Champalimaud Center is the first building in a major redevelopment plan to change the face of the Lisbon riverfront. The anticipated inauguration date for the Center is October 5th, 2010.

About the Champalimaud Foundation:

The Champalimaud Foundation supports individual researchers and research teams working at the cutting edge of medical science. It aims to stimulate novel theoretical and practical methodologies by utilizing the experience of both research scientists and medical practitioners, connecting pure scientific investigation with applied clinical research. The Champalimaud Foundation aims to maximize the work being done in the fields of cancer research and neuroscience, including stem cell research and its clinical applications for Parkinson's and Alzheimer's disease, diabetes and spinal injury. It is named for Antonio Champalimaud, who was the richest man in Portugal when he died in 2004, bequeathing a quarter of his $3.1 bi
'/>"/>

SOURCE The Champalimaud Foundation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Carlson Hotels Worldwide Partners With the American Red Cross in Texas to Provide Relief for Children Affected by Hurricane Ike
2. Many Military Installations Worldwide Participate in National Depression Screening Day
3. Discover a World of Savings with Health Savings Accounts (HSAs)
4. Argentyn 23(R) Homeopathic First Aid Gel - Another Worlds First by Natural-Immunogenics Corp. for Healthcare Professionals
5. Reflex Stock Launches Exciting New Editorial Image Collections to the Worldwide Publishing Industry
6. Scripps Research Institute and IAVI launch worlds first dedicated HIV neutralizing antibody center
7. $9 Million Committed to Bolster Worldwide Measles Initiative
8. HTH Worldwide Welcomes New Chief Financial Officer
9. World Alzheimer's Day 2008 Special Report: New Alzheimer Targets Take Center Stage
10. (Report) World Privacy Forum Publishes Red Flag Rule Suggestions for Hospitals and Providers; New FTC-Enforced Rules Go Into Effect Nov. 1, Can Apply to Health Care Providers
11. New Lottery Ticket Envisions a World Free of MS
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies 2The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies 3The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies 4The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies 5Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program 2Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program 3TaiGen Biotechnology Reports Phase I and Preclinical Data for TG-0054 at the 2009 American Society of Hematology (ASH) Annual Meeting 2The People 26apos 3Bs Medicine Community Certified to Display TRUSTe Privacy Seal of Approval 55795 1The People 26apos 3Bs Medicine Community Certified to Display TRUSTe Privacy Seal of Approval 55795 2The People 26apos 3Bs Medicine Community Certified to Display TRUSTe Privacy Seal of Approval 55795 3Two Powerful Companies One Powerhouse in Protection 55790 1Two Powerful Companies One Powerhouse in Protection 55790 2Chemotherapy for breast cancer is associated with disruption of sleep wake rhythm in women 55788 1Chemotherapy for breast cancer is associated with disruption of sleep wake rhythm in women 55788 2Chemotherapy for breast cancer is associated with disruption of sleep wake rhythm in women 55788 3